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Abstract Transcranial Doppler can detect microembolic signals, which are char-
acterized by unidirectional high intensity increase, short duration, and random
occurrence, producing a ‘‘whistling’’ sound. Microembolic signals have been proven
to represent solid or gaseous particles within the blood flow. Microemboli have
been detected in a number of clinical cardiovascular settings: carotid artery steno-
sis, aortic arch plaques, atrial fibrillation, myocardial infarction, prosthetic heart
valves, patent foramen ovale, valvular stenosis, during invasive procedures (angiog-
raphy, percutaneous transluminal angioplasty) and surgery (carotid, cardiopulmo-
nary bypass). Despite numerous studies performed so far, clinical significance of
microembolic signals is still unclear. This article provides an overview of the devel-
opment and current state of technical and clinical aspects of microembolus
detection.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Embolization is the cause of ischemic stroke in 40e
80% of cases.1 Transient ischemic attack (TIA) is
a warning sign of stroke; it is often caused by em-
boli lodged in a distal artery that underwent suc-
cessful anastomosis or lysis.2 In the last 15 years
a substantial number of studies dealing with
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doi:10.1016/j.ijsu.2005.12.001emboli detection have been performed, while
the clinical relevance of so-called microembolic
signals (MES, old terminology was high intensity
transient signals HITS) is still under debate. MES
are proven to represent emboli passing within
cerebral circulation.2 Emboli are particles of
platelets, fibrinogen, cholesterol, fat, particles of
disrupted plaque (trombus) or gas bubbles that
travel through circulation. First studies on emboli
detection have been performed in the 1960s.3 In
1990 Spencer et al. reported on patients undergo-
ing carotid endarterectomy (CEA) in whomblished by Elsevier Ltd. All rights reserved.
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ing the preparation phase of the artery, before
opening of the artery lumen; detected microem-
bolic signals (MES) were assumed to represent
emboli.4 Ever since, emboli have been detected
in a number of cardiovascular conditions: carotid
artery stenosis, aortic arch plaques, atrial fibrilla-
tion, myocardial infarction, prosthetic heart
valves, patent foramen ovale, valvular stenosis,
during carotid surgery, open heart surgery, stent
implantation, percutaneous transluminal angio-
plasty, and angiography.5e15 Clinical significance
of emboli detected in cerebral circulation is still
unclear. While the vast majority of microembolic
signals (MES) are asymptomatic, there is substan-
tial evidence at disposal that MES are relevant in
certain clinical conditions. Consensus regarding
emboli detection has been made, since different
researchers had different identification criteria
for emboli. The most important technical parame-
ters affecting the detectability of microembolic
signals are as follows15:
1. Relative intensity increase e ratio of the
acoustic power backscattered from the embo-
lus to that of the moving blood surrounding
the embolus; it is usually measured in decibels.
2. Detection threshold e ranging from 3 to 9 dB
has been recommended.
3. Size of the sample volume e most investigators
use a value of sample volume length between
3 and 10 mm.
4. Fast Fourier Transform (FFT) frequency resolu-
tion and temporal resolution e the frequency
resolution is given by the reciprocal of tempo-
ral resolution; the greater the number of points
used for the FFT the poorer the temporal reso-
lution; therefore a compromise is necessary.
At present 64, 128 or 256 frequency bins are
preferred.
5. Fast Fourier Transform (FFT) temporal overlape
FFT overlap of at least 50% is essential; smaller
overlaps (e.g., 10%) impose the risk of missing
individual microembolic signals.
6. Dynamic range of the instrumentation e a wide
dynamic range prevents overloading of the
receiver. Dynamic range depends on the manu-
facturer; devices presently marketed have
dynamic ranges on the order of 30e50 dB.
7. Transmitted ultrasound frequency e a fre-
quency of 2 MHz is most frequently used; the
sensitivity is lower with higher frequencies.
8. Filter settings e high-pass filters suppress low
frequencies originating from arterial wall oscil-
lation; the level of high- and low-pass filters
should be kept constant.9. Recording time e it depends on the study pop-
ulation (see below).
Characteristics of microembolic signals
(MES)
1. Short lasting (<0.01e0.03 s) intensity increase,
2. unidirectional intensity increase (>3 dB) within
the Doppler frequency spectrum,
3. intensity increase focused around one
frequency,
4. random occurrence within the cardiac cycle,
5. produce a ‘‘whistle’’, ‘‘chirping’’ or ‘‘clicking’’
sound when passing through the sample
volume.
Artifacts
Artifacts also cause intensity increase of Doppler
spectrum. Artifacts can be caused by patient
moving the head, coughing, chewing or any move-
ment that are causes by artifacts will be present as
bidirectional (above and under the zero line).
Large, solid emboli or gaseous emboli may cause
overload of the receiver which can produce similar
signals as artifacts. Therefore it is important that
the transcranial Doppler sonography (TCD) ma-
chine has a wide dynamic range (at least 50 dB).
Artifacts cause intensity increase usually of low
frequency, around the zero line and produce
sounds like ‘‘rumble’’.16
Materials and methods
TCD machine should have a special software for
emboli detection with a sufficient dynamic range.
Two 2 MHz frequency probes should be connected
to a band or aluminum wire which is placed on
the patient’s head. The machine should have auto-
matic saving of every change of Doppler spectrum
caused by frequency shift, so detailed analysis can
be performed later as many times as required.
Video taping of the recordings is even better
because not all softwares have the possibility to
reproduce sound which is an important character-
istic of emboli. Fast Fourier transform (FFT) signal
processing is widely used in the evaluation of mi-
croembolic signals (MES). In FFT based calcula-
tions, the time window overlap is of considerable
importance; MES falling between two FFT intervals
are likely to appear smaller than those in the mid-
dle, and if the overlap is very small MES can even
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insufficient overlaps, if older technology is being
used, then window overlap should be taken into
consideration when assessing MES.17 New TCD ma-
chines, ‘‘multigate Doppler’’, enable better differ-
entiation of emboli from artifacts. Two sample
volumes are placed at a distance of at least
5 mm, one from another, which enable recording
of Doppler spectrum at two depths of an artery.
When the embolus is moving from proximal to dis-
tal part of the artery, it passes two gates (sample
volumes) and is then recorded twice with a delay
in time, showing in the spectrum as two different
appearances. Artifacts are recorded simulta-
neously in both sample volumes and make the
same appearance. The main criterion for differen-
tiation of MES and artifacts in multigate Doppler
machines is time difference of MES.18 Emboli anal-
ysis other than FFT calculation is being improved
with other methods such as Wigner distribution
function, narrow band hypothesis, non-linear fore-
casting, frequency filtering of time domain data,
and wavelet transformation.19 A new transcranial
modality, power M-mode Doppler (PMD), has
been developed to overcome the difficulties in
location and insonation through transcranial ultra-
sound windows. PMD has 33 sample gates placed
with 2-mm spacing for display of Doppler signal
power, colored red and blue for directionality, in
an M-mode format. The spectrogram from a user-
selected depth is displayed simultaneously. PMD
facilitates window location and alignment of the
ultrasound beam to view blood flow from multiple
vessels simultaneously, without sound or spectral
clues. Microemboli appear as characteristic sloping
high-power tracks in the power M-mode Doppler
(PMD) image.20 Although technological improve-
ment in the area of emboli detection has recently
been achieved, it is still impossible to reliably
distinguish the composition of emboli. In vivo and
in vitro studies have tried to differentiate gaseous
from solid emboli. Differentiation between solid
and gaseous microemboli is based on the principle
that solid emboli reflect more ultrasound at higher
frequency, whereas the opposite is the case for
gaseous emboli. This principle is used in multifre-
quency TCD instrumentation where the vessels
are insonated simultaneously with 2.5 and 2.0 MHz
and can be used for the differentiation between
gaseous and solid emboli.21 Differentiation of solid
and gaseous emboli has also been demonstrated by
oxygen inhalation.12 Intensity, duration and fre-
quency are useful to distinguish between the
two, however, it is still impossible to differentiate
between particles of fat, platelet aggregates or
particles of atheroma.22The aluminum wire (or tight rubber band) is
placed on the patient’s head, and both middle
cerebral arteries (MCA) are insonated through
temporal windows. When the Doppler signal is
located, it is important to achieve a clear signal
from the depth of 45e55 mm; insonation too close
to the carotid siphon may result in recordings of
false positive signals which are caused by blood
turbulence.23 At 45e55 mm depths the blood
stream is mostly laminar and turbulence is not ex-
pected. After achieving a clear signal, the probes
are fixed; monitoring is performed over at
least 1 h (extended monitoring is preferable is
cooperative).
Monitoring time
Optimal time of monitoring depends on the
clinical entity. In patients with implanted artifi-
cial heart valves in whom microembolic signals
(MES) can be detected in large proportion, mon-
itoring for 30 min will be sufficient. In patients
with atrial fibrillation or other cardiac disease,
or carotid artery stenosis the frequency of emboli
is usually low, 1e2 emboli signals over 60 min.
Extended monitoring, for more than 1 h, or repet-
itive monitoring over a couple of days in succes-
sion, is in relation with the percentage of
emboli positive patients.24,25 Embolic activity is
highest in the first couple of hours after stroke;
however, emboli may be detectable days and
weeks after cerebrovascular incidents, which
means that those patients are at a higher risk of
stroke.26,27 It must be highlighted that patients
who have no recorded emboli signals (even on
repetitive monitoring) cannot be declared as
‘‘emboli negative’’. However, patients who have
detectable emboli, especially in larger numbers,
should be considered as high risk patients for
stroke. Emboli detection may help in the localiza-
tion of embolic source: emboli detected in both
middle cerebral arteries (MCAs) are usually from
cardiac source, and emboli detected ipsilaterally
to a carotid artery stenosis are probably dislodged
from intraluminal thrombus or plaque disrup-
tion.28,29 Although emboli monitoring is consid-
ered as a safe and noninvasive method, a small
number of studies have focused on this issue. In
vivo studies have shown that bilateral monitoring
of middle cerebral arteries (MCA) with 530 mW/
cm3 over 8 h caused no abnormal immediate or
late changes of the tissue, as shown on histologic
specimens; the power used in this study exceeded
the power which is used in commercial TCD
machines.30
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Cerebral microemboli can be detected in a variety
of cardiovascular conditions and may help in the
localization of embolic source. Emboli detection
may help in the cardiac sources of emboli with
major or minor significance, arterial source of
emboli and in monitoring during invasive proce-
dures and surgery.
[1] Localizations of cardiac embolic sources with
major significance are as follows:
Atrial fibrillation
Valvular (mitral) stenosis
Myocardial infarction
Thrombus in left ventricle
Infective endocarditis
Myxoma in the left atrium
Dilated cardiomyopathy
[2] Localizations of cardiac embolic sources with
minor significance are as follows:
Mitral valve prolapse
Patent foramen ovale
Aneurysm of atrial septum
Valvular (aortic, mitral) calcifications
Prosthetic heart valve
[3] Emboli detection may also help in the localiza-
tion of arterial sources of emboli, which are as
follows:
Atherosclerotic artery disease
Carotid stenosis
Intracranial artery stenosis
Aortic arch plaques
Dissection of carotid arteries
Aortic aneurysm
[4] Cerebral microemboli can be detected by mon-
itoring during invasive procedures and surgery.
For example:
Cardiopulmonary bypass
Carotid endarterectomy
Angiography
Percutaneous transluminal angioplasty
Cardiac diseases
Stroke is a relatively frequent complication in
patients with cardiac diseases; 15e30% of strokes
are caused by cardiac diseases.11 Clinical and epi-
demiological observations show that patients with
thrombi in left ventricle, atrial fibrillation and
other cardiac diseases have a higher risk of contin-
uous embolization; these observations have been
substantiated by the presence of microembolic sig-
nals (MES) in cerebral circulation detected by TCD
in patients with such conditions.31,32 Prospectivestudies have shown that recurrent stroke of sys-
temic embolization is high in this group of
patients, up to 20%.33,34 Strokes due to embolism
of cardiac origin are in general severe and prone
to early and long-term recurrence. Embolism of
cardiac origin can be reliably suspected on clinical
grounds but is often difficult to document.
Atrial fibrillation
Atrial fibrillation (AF) is a frequent cardiac rhythm
disorder in older patients. AF is present in 1.7% of
the population aged 60e64, and in 6% of the
population older than 75 years.35 The incidence
of stroke in patients with AF is 4.5% per year.36 In
cases when AF is associated with mitral valve ste-
nosis, the risk of stroke is 17 times higher.37 The
majority of strokes in patients with AF are embolic
in origin; emboli signals can be detected in 15e
30%.38,39 Paroxysmal AF is also considered a risk
factor for stroke; the incidence of embolic inci-
dents in patients with paroxysmal AF is similar to
that in patients with chronic AF.40 Ischemic stroke
is more severe than in patients with sinus rhythm,
the outcome is often fatal; in survivors recurrent
stroke is more frequent and neurologic deficit is
more severe.41,42 Emboli detection in patients
with AF can reveal patients at a high risk.
Valvular stenosis
Spontaneous echo contrast can be visualized by
transesophageal echocardiography, it appears like
a ‘‘swirl’’ or a ‘‘cloud’’ in left atrium and left
appendage.43 This phenomenon is due to erythro-
cyte aggregation in the presence of macromole-
cules in conditions of blood stasis.44 Spontaneous
echo contrast is present in patients with AF,
dilated atrium and left appendage, prosthetic
mitral heart valves and severe ventricular dysfunc-
tion.44 Echo contrast is an independent risk factor
for thrombus formation in left atrium and for
systemic embolization.45
Myocardial infarction
Approximately 2.5% of patients with acute myocar-
dial infarction (MI) will have stroke within 2e4
months.45 Patients with anterior wall infarct have
a stroke risk of 6%, and those with inferior wall
(MI) 1%.46 In a prospective study in patients with an-
terior wall (MI), emboli signals could be detected in
21%.46 Mobile thrombi in left ventricle, anterior and
apical localization as well as size of dyskinetic wall
segment have a predictive value for stroke.45
236 N. Hudorovic´Infective endocarditis
The prevalence of stroke in patients with infective
endocarditis is 15e20%.47 The size of vegetations
has a predictive value, the risk of embolization is
higher in patients with vegetations larger than
10 mm, and in patients with endocarditis of mitral
and mobile vegetations.47
Cardiac tumors
Although rare, atrial myxoma is the most frequent
primary cardiac tumor, usually present in the left
atrium. Due to its fragile nature, myxoma has
a high potential for embolization to the brain as
well as to other organs.46
Dilated cardiomyopathy
Impaired systolic function results in low ejection
fraction; when becomes significant, as a frequent
complication mural thrombi are being formed.45
The incidence of embolic complications in patients
with cardiomyopathy is 4% per year.45 Embolic sig-
nals are detectable in 1/3 of patients with dilated
cardiomyopathy.11
Mitral valve prolapse
The prevalence of mitral valve prolapse (MVP) in
the general population is 1e15%.48 Isolated MVP
is not considered as a significant risk factor for
stroke in older patients, but in younger patients
myxomatous change of mitral valves is consid-
ered to be in relationship with cerebrovascular
incidents.48
Patent foramen ovale
The prevalence of patent foramen ovale (PFO) in
the general population is 22e34.4%.49,50 In pa-
tients with so-called cryptogenic stroke due to
paradoxical embolism, especially younger pa-
tients, a high prevalence of patent foramen ovale
(PFO) has been found.51,52 The average annual
rates of recurrent cerebral ischemia were 3.6%,
and for recurrent strokes were 9.9%.53 TCD has
shown to be highly specific and sensitive, and
may serve as an excellent alternative method to
the gold standard of transesophageal echocardiog-
raphy (TEE) in the diagnosis of PFO.54 When per-
forming transesophageal echocardiography (TEE),
the presence of patent foramen ovale (PFO) is
confirmed if gas bubbles are seen within three
cardiac cycles after contrast injection; and whileperforming TCD microbubbles (MB) are detected
in the middle cerebral artery (MCA) 10 s after
injection of contrast agent prepared as agitated
isotonic saline solution in the cubital vein.55 Val-
salva maneuver performed during contrast injec-
tion increases the sensitivity. Patent foramen
ovale (PFO) has shown to be a significant risk
factor for stroke in younger patients. Two factors
have been identified as factors that potentially
increase the risk of stroke:
[1] Patent foramen ovale (PFO) associated with
right-to-left shunt (RLS) e A multicenter study
has shown that stroke risk over 4 years is 19.2%
in patients with PFO and RLS, and only 5.6% in
patients with isolated PFO.56
[2] Size of patent foramen ovale (PFO) e A study
has shown that PFO >2 mm is present in
a higher proportion of patients with crypto-
genic stroke (26%) than in patients with identi-
fied cause (6%).57 Another study has shown the
size of PFO to be >4 mm in patients with stroke
as opposed to the healthy control group with
the size of PFO <2 mm.58 As a method for the
evaluation of the size of PFO the detection of
microbubbles (MB) in the MCA under basal con-
ditions after i.v. contrast or agitated saline
injection has been proposed; a four level cate-
gorization according to microbubbles’ (MB)
count should be applied.55
a) 0 MB e negative result
b) 1e10 MB e small PFO
c) >10 MB e large PFO
d) curtain e ‘‘shower’’ [curtain refers to a
shower of microbubbles (MB), where a single
bubble cannot be identified]
A clinical study has shown that the presence of
‘‘curtain’’ correlates with the highest risk of
stroke.59 The size of right-to-left shunt estimated
with TCD may not be in correlation with the size
of patent foramen ovale (PFO) estimated with
echocardiography, as other factors can influence
the blood volume that passes through the shunt.60
Patent foramen ovale (PFO) is present in a high
percentage in scuba divers with complications
due to decompression disease; the risk is 2.5e4.5
times higher in patients with PFO.61,62 TCD can
serve as an excellent screening method for the de-
tection and size of right-to-left shunt; transeso-
phageal echocardiography (TEE) is indicated in
shunt positive patients to confirm the localization
of the shunt, and to investigate the presence of
patent foramen ovale (PFO) or other cardiac
abnormalities.
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Carotid stenosis
Detection of emboli ipsilaterally to carotid stenosis
may localize the source of emboli, help in the
classification/ etiology of cerebrovascular symp-
toms, and indicate asymptomatic patients with
higher stroke risk. The frequency of embolic
signals is higher in patients with higher grade of
carotid stenosis; stenosis <29% is not prone to
embolization, 30e69% stenosis may in certain
conditions produce emboli, and stenosis >70% is
prone to embolization.63,64 Plaque characteristics
are also important: intraluminal thrombosis, irreg-
ular plaque surface, and ulceration are in relation
with emboli frequency.65,66 Studies have shown
great variability of detected emboli in patients
with carotid stenosis, however, all studies are con-
sistent in the observation that the frequency of
emboli in asymptomatic patients is significantly
lower. In one study symptomatic patients with se-
vere carotid stenosis were emboli positive in 77%,
and asymptomatic in only 16%.67 In another study
emboli were detected in 27% of symptomatic and
2.9% of asymptomatic patients.68 In several studies
a shorter time interval between stroke and moni-
toring was related to the frequency of detected
emboli.69,70 Most of the patients with severe
carotid stenosis will eventually produce micro-
emboli. However, the production of emboli is
random, and it is likely that many hours of moni-
toring are required to determine whether a patient
with symptomatic carotid diseases is emboli posi-
tive. Microemboli in these patients can help in
the identification of the patients at risk and fur-
thermore indicate periods of transiently increased
risk in individual patients.71 After carotid endar-
terectomy, emboli signals disappear or the fre-
quency is significantly lower.72 Dissection of
carotid arteries is an embolic source, and emboli
can be detected in a high proportion of these
patients.73 TCD was used to monitor cessation of
ipsilateral distal microembolization associated
with clinical improvement on anticoagulant ther-
apy. The presence of emboli in cerebral circulation
can be regarded as a risk factor for stroke.74e76
Aortic arch atheroma
Aortic arch atheroma has long been underesti-
mated as an embolic source. Studies have shown
that aortic arch atheroma is a strong and indepen-
dent risk factor for ischemic stroke. The risk of
stroke increases sharply in patients when the
thickness of plaques is greater than 4 mm; the at-
tributable stroke risk is 12.6%; microembolic sig-
nals can be detected in 14.3% of these patients.77Monitoring during invasive procedures
Cardiopulmonary bypass
The first of the four decades of cardiac surgical
history showed the greatest progress; however,
postoperative transient or persistent neurologic
deficit is present in a large proportion of patients.
Perioperative stroke occurs in 2e3% of adult
cardiac surgery patients and significant cognitive
dysfunction is experienced by 40e60% of patients
in the first postoperative week.78 Perioperative
neurocognitive abnormalities are associated with
a greatly increased risk of perioperative mortality,
lengthy intensive care and hospital stay. Long-
term cognitive dysfunction, ranging from months
to years, occurs in 25e40% of patients resulting
in a decreased quality of life.78 The exact patho-
physiological mechanism responsible for postcoro-
nary artery bypass graft (CABG) deficit is not clear;
the two most important are hypoperfusion and
microembolism. In patients with postoperative
neurologic deficit can be detected twice as high
as in patients without emboli signals in cerebral
circulation.7 Neurologic deficit was present eight
weeks postoperatively in 8.6% of patients in
whom <200 emboli during CABG were detected,
and in 43% of patients with 1000 detectable emboli
per surgery.79 Improvement of technology results
in better postoperative outcome: the introduction
of filters has resulted in a lower incidence of neu-
rologic lesions (5%) as compared with patients who
had the surgery performed with unfiltered ma-
chines (27%).79 Observations from these and simi-
lar studies indicate that microembolization could
be a significant cause of neurologic and cognitive
deficits in patients after CABG.
Carotid endarterectomy (CEA)
Prospective studies in patients with high grade
carotid stenosis have shown that stroke occurred
in patients with cerebral microemboli detected
with TCD who had not had a surgery; the risk
significantly decreased after CEA and emboli signals
had disappeared or significantly decreased.80 Em-
boli signals can be detected during the exposure
and mobilization of the artery, especially during
implantation and removal of the shunt and after
clamp release.81 The efficacy of CEA largely de-
pends on postoperative results, i.e. perioperative
complications. Intraoperative monitoring of hemo-
dynamic changes and detection of microbubbles
(MB) may significantly influence postoperative
outcome.82 A study in 500 patients has shown that
microemboli detected during surgery are the prob-
able cause of cerebrovascular complications in
54%; the incidence of persistent neurologic deficit
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surgeries) to 2% (documented in the next 400 sur-
geries) when surgeons changed the operative strat-
egy according to intraoperative TCD information.81
Percutaneous transluminal angioplasty (PTA)
Advantages and disadvantages of PTA as compared
with classic CEA are still a matter of debate. Main
disadvantages are attributed to the higher risk of
neurologic complications due to hemodynamic
ischemia during balloon inflation and microembo-
lization after plaque disruption. Studies have
shown inconsistent results. Several studies have
shown that despite higher frequency of detected
emboli, stroke risk was not higher in patients in
whom PTA was performed, whereas others put in
doubt the advantages of PTA due to the high
frequency of emboli and complications during the
procedure.83 The use of cerebral protection de-
vices appears to reduce thromboembolic complica-
tions during PTA and stenting; the combined stroke
and death rate within 30 days in patients treated
with cerebral protection devices was 1.8% as com-
pared with 5.5% in patients without these de-
vices.84 Experimental studies have shown that
the majority of microbubbles (MB) are gaseous in
origin, whereas microbubbles (MB) detected during
balloon inflation are probably attributable to solid
particles.85
Angiography
Angiography of the aortic arch is associated with
1% risk of stroke with permanent deficit, and 3%
risk of mild to moderate stroke or TIA.8,9 In a study
with 24 patients undergoing angiography one mid-
dle cerebral artery was monitored with TCD for ca-
rotid territory ischemia. Microemboli were seen in
all patients, with an average of 51 (range 12e154)
per procedure, the majority of emboli signals had
the characteristics of gas bubbles; the number of
detected microbubbles (MB) correlated with the
volume of injected contrast, and all patients
except one who had stroke were asymptomatic.9
Microbubbles (MB) detected during angiography
are attributable to gas bubbles, contrast injection,
clot formation in catheter, and disrupted athero-
matous material.8,9,86,87
Discussion
Coagulation
Coagulation mechanisms in patients with stroke,
TIA, coronary and other cardiac diseases are notfully understood. Clinical studies have shown that
hyperfibrinogenemia is in positive correlation with
cardiovascular and cerebrovascular diseases.88,89
Patients with progressive atherosclerosis have
higher levels of fibrinogen compared with those
with nonprogressive disease.90 Patients with fibrin-
ogen blood level >5 g/L have fourfold risk of
thromboembolic complications.91 Embolic signals
are detectable with a higher frequency in patients
with higher fibrinogen levels.88
Monitoring of therapeutic efficacy
Monitoring of therapeutic effect has shown that
after CEA emboli disappear or decrease in fre-
quency, a finding consistent across studies.91,92
Studies that investigated the efficacy of anticoag-
ulant and antiaggregation therapy and frequency
of emboli have shown various results. Although
some studies have shown a decrease in emboli fre-
quency after aspirin or heparin administration,
consistent correlation has not been found. How-
ever, the CARESS trial (first multicenter, random-
ized, double blind trial that used microembolic
signals’ (MES) detection as endpoint to evaluate
antiplatelet therapy) has shown that clopidog-
relþ aspirin is superior to aspirin alone in reducing
the frequency of microembolic signals (MES) in pa-
tients with recent symptomatic carotid stenosis.
Monitoring of therapeutic efficacy has been consis-
tent after CEA.93e95 S-Nitrosoglutathione (GSNO) is
a nitric oxide donor that appears to have relative
platelet specificity. The administration of S-
nitrosoglutathione (GSNO) in patients with carotid
artery stenosis resulted in a rapid reduction in the
frequency of embolic signals of 84% at 0e3 h, 95%
at 6 h, and 100% at 24 h. Despite its short half-
life, S-nitrosoglutathione (GSNO) proved highly
effective in rapidly reducing the frequency of em-
bolic signals in this group.96 Glycoprotein IIb/IIIa
receptor antagonist tirofiban is a highly selective
platelet aggregation inhibitor. The administration
of tirofiban resulted in microembolic rate drop
from a median range of 38 to zero in patients
with severe carotid artery stenosis, however, the
inhibitory effect of tirofiban is reversible.97
Clinical significance of emboli detection
Clinical significance of emboli detection is not
fully elucidated; numerous studies have shown
various results. A significantly higher frequency of
emboli signals was detected in patients with
acute stroke when monitoring was performed
within the first couple of hours as compared to
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are detectable later more frequently have
recurrent stroke, often fatal. A certain proportion
of patients with detectable emboli signals are
asymptomatic, although correlation of cerebral
microemboli with clinical symptoms (stroke or TIA
ipsilateral to carotid stenosis, higher incidence of
stroke in patients with cardiac diseases, neuro-
logic complications after angiography, postopera-
tive neurologic complications after CEA, in
patients after CABG) was shown in a number of
studies. It is important to emphasize that the vast
majority of emboli do not produce immediate
symptoms. Great variability of results demon-
strated in various studies is attributable to the
small number of included patients, inhomoge-
neous groups, different TCD machines and equip-
ment settings, and different criteria for emboli
characterization. Despite disputable clinical sig-
nificance in certain conditions, the potential
benefit of TCD emboli detection is substantial.
Emboli in cerebral circulation indicate asymptom-
atic patients with increased stroke risk. In symp-
tomatic patients the etiology of neurologic deficit
may be elucidated and appropriate therapy in-
troduced. Emboli detection may help in differen-
tiation between hemodynamic and embolic
stroke. In certain cases emboli detection may
indicate the embolic source; in patients with
carotid stenosis emboli signals will be detected
ipsilaterally to the stenosis, whereas in patients
with cardiac diseases emboli can be detected in
both middle cerebral arteries (MCAs), or in all
cerebral arteries. Patients with cerebral micro-
embolism have higher cognitive deficits; cumula-
tive effect of embolism is thought to be the
cause. Even a minor neuropsychological impair-
ment should not be underestimated, and the
presence of an embolic source should be regarded
as the possible cause of cognitive decline. Imaging
techniques (computed tomography, magnetic
resonance, diffusion-weighted magnetic reso-
nance image) can show ‘‘silent’’ areas of cerebral
ischemia; these small and multiple areas of acute
or subacute brain infarction may occasionally
present with clinical features atypical for brain
embolism or will not produce any apparent symp-
toms.98 Besides the size and composition of em-
boli, other factors play a role in asymptomatic/
symptomatic patients; these factors probably in-
clude collateral circulation and characteristics of
the recipient vessel. Multicenter studies with
a large number of patients and standardized mon-
itoring protocols are needed to elucidate the clin-
ical significance of emboli signals in cerebral
circulation.References
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